Overview
Acute lower respiratory tract infections (ALRTIs) represent a significant global health burden, particularly among pediatric populations. These infections encompass a range of conditions from common colds to severe pneumonia and bronchiolitis. Epidemiological studies highlight the diverse viral etiologies contributing to ALRTIs, including human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). The impact of environmental factors, such as air pollution and indoor particulate matter (PM), further complicates the epidemiology, influencing both incidence and severity. Understanding the seasonal patterns and demographic susceptibilities is crucial for effective prevention and management strategies.
Epidemiology
The epidemiology of ALRTIs is marked by significant variability in viral prevalence and environmental influences. A longitudinal study conducted from September 2007 to February 2011 in Changsha, China, detected hMPV in 5.2% (135/2613) of nasopharyngeal aspirate specimens from children with lower respiratory tract infections [PMID:25950091]. This study revealed a dynamic shift in hMPV genotypes over time, initially dominated by A2b, which transitioned to a mix of A2b and B1, eventually settling predominantly with genotype B1. This genotype variability underscores the need for continuous surveillance to monitor viral evolution and its implications on disease severity and transmission dynamics.
Environmental factors, particularly exposure to indoor air pollutants, significantly impact ALRTI incidence. Children under 5 years of age exposed to smoke from biomass fires were found to be 1.8 times more likely to experience acute lower respiratory infections compared to unexposed children [PMID:23127494]. This highlights the critical role of indoor air quality, especially in regions where biomass fuel is commonly used for cooking and heating. Seasonal patterns of indoor particulate matter (PM) concentrations are essential to consider, as they correlate with increased risks of ALRTIs, emphasizing the importance of targeted interventions to reduce exposure during peak periods [PMID:23127494].
Recent data from pediatric inpatients between 2023 and 2024 further elucidate the epidemiology of ALRTIs, with RSV identified in 10.2% (2035/19,923) of cases [PMID:41690416]. These findings reveal distinct seasonal patterns and age-specific variations in RSV detection rates, indicating that certain age groups may be more vulnerable during specific times of the year. Additionally, complex interactions between meteorological factors and air pollutants, such as temperature, humidity, CO, NO2, and PM2.5, were explored using distributed lag nonlinear models (DLNM). These models indicated intricate relationships that influence RSV detection rates, suggesting that environmental conditions play a multifaceted role in ALRTI epidemiology [PMID:41690416].
Air pollution, particularly particulate matter (PM2.5, PM10, and PMc), has been consistently linked to increased ALRI hospitalizations. A multi-city time-series analysis in China demonstrated that daily mean exposure to PM2.5 was associated with a 2.43% (0.79%, 4.11%) increase in ALRI hospitalizations, with similar trends observed for PM10 and PMc [PMID:34774633]. Notably, the effects were more pronounced during colder seasons, indicating seasonal variations in susceptibility to air pollution-induced respiratory infections. The identification of DECH (Daily Exposure to Concentrations of Hazardous Air Pollutants) as a potential alternative exposure indicator for PM2.5 could inform future air quality standards and risk assessments for respiratory infections, offering a pathway for more precise public health interventions [PMID:34774633].
Clinical Presentation
The clinical presentation of ALRTIs varies widely but often includes common respiratory symptoms. In children infected with hMPV, the most frequent symptoms include cough, fever, and wheezing, with no significant differences noted between different hMPV genotypes [PMID:25950091]. These symptoms align with those typically seen in other viral respiratory infections, making clinical differentiation challenging without laboratory confirmation. Wheezing, in particular, can mimic or coexist with asthma exacerbations, necessitating careful assessment to rule out other respiratory conditions.
RSV infections present similarly complex clinical scenarios, often with overlapping symptoms. Among 2035 RSV-positive cases studied, 44.0% (891 cases) experienced co-infections, highlighting the complexity and variability in clinical presentations [PMID:41690416]. Co-infections can exacerbate symptoms and prolong illness duration, underscoring the importance of comprehensive diagnostic testing to identify all pathogens involved. This complexity necessitates a holistic approach to patient management, considering both primary and secondary pathogens to tailor appropriate treatment and supportive care.
Differential Diagnosis
Differentiating ALRTIs from other respiratory conditions is crucial for effective management. Co-infection with other respiratory viruses is a notable consideration, particularly in hMPV-positive cases where 45.9% (62/135) involved co-infections, with human bocavirus being the most frequently detected co-pathogen [PMID:25950091]. These co-infections can complicate clinical presentations, making it essential to employ multiplex PCR panels to identify all potential pathogens. Other differential diagnoses include bacterial pneumonia, asthma exacerbations, and viral bronchiolitis, each presenting with overlapping symptoms such as cough, fever, and respiratory distress. Clinical judgment, supported by laboratory and imaging findings, is vital in distinguishing between these conditions to guide appropriate therapeutic interventions.
Diagnosis
Diagnosing ALRTIs involves a combination of clinical assessment and laboratory testing. Initial evaluation typically includes a thorough history and physical examination to identify key symptoms such as cough, fever, and respiratory distress. Laboratory diagnostics play a pivotal role, with nasopharyngeal swabs being crucial for viral detection. Techniques like PCR (polymerase chain reaction) are highly sensitive and specific for identifying hMPV, RSV, and other respiratory viruses [PMID:25950091, PMID:41690416]. Chest imaging, including X-rays or CT scans, may be necessary to rule out complications like pneumonia or to assess the extent of lung involvement, especially in severe cases.
Given the high prevalence of co-infections, particularly with RSV, clinicians should consider multiplex testing panels that can simultaneously detect multiple pathogens. This approach not only aids in accurate diagnosis but also informs targeted treatment strategies, especially when managing co-infections [PMID:41690416]. Additionally, monitoring biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) can help differentiate between viral and bacterial etiologies, guiding decisions on antibiotic use where necessary.
Management
The management of ALRTIs focuses on supportive care and targeted interventions based on the severity of symptoms and identified pathogens. For mild cases, supportive care includes ensuring adequate hydration, maintaining oxygenation, and providing symptomatic relief through antipyretics for fever and bronchodilators for wheezing [PMID:25950091]. In more severe cases, hospitalization may be required for close monitoring, oxygen therapy, and advanced respiratory support if needed.
Antiviral therapies are limited for most viral causes of ALRTIs, with ribavirin being an exception used primarily in immunocompromised patients for RSV infections [PMID:25950091]. For co-infections, particularly those involving bacterial pathogens, empirical antibiotic therapy may be warranted based on clinical suspicion and local resistance patterns, though this should be guided by culture results when available.
Environmental interventions are also crucial, especially in regions with high indoor air pollution. Reducing exposure to particulate matter and improving indoor air quality through ventilation and air filtration can mitigate the risk of exacerbations and reduce the overall burden of ALRTIs [PMID:23127494, PMID:34774633]. Public health measures, such as vaccination campaigns (where available, e.g., for influenza) and education on smoke exposure reduction, further contribute to preventive strategies.
Key Recommendations
References
1 Zeng SZ, Xiao NG, Zhong LL, Yu T, Zhang B, Duan ZJ. Clinical features of human metapneumovirus genotypes in children with acute lower respiratory tract infection in Changsha, China. Journal of medical virology 2015. link 2 Gurley ES, Salje H, Homaira N, Ram PK, Haque R, Petri WA et al.. Seasonal concentrations and determinants of indoor particulate matter in a low-income community in Dhaka, Bangladesh. Environmental research 2013. link 3 Zhang S, Chen C, Wang R, Liu L, Wang X, Zhang X. Influence and lagged effects of weather and air pollution on pediatric RSV-ALRI in Shenyang, NE China. Respiratory medicine 2026. link 4 Liang Z, You C, Zhang X, Wang X, Xiao D, He S et al.. Three exposure metrics of size-specific particulate matter associated with acute lower respiratory infection hospitalization in children: A multi-city time-series analysis in China. The Science of the total environment 2022. link